Ladenburg Thalmann analyst Wangzhi Li sees a 'large, unwarranted' undervaluation for Trillium Therapeutics (NASDAQ: TRIL) and reiterated a Buy rating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE